Bevacizumab is an anti-VEGF recombinant humanized monoclonal IgG1 antibody used to treat colorectal cancers. Bevacizumab may have a role in treating ocular disorders involving fibrovascular proliferation. Rubeosis iridis or neovascularization of iris is a medical condition of the eye in which new abnormal blood vessels are found on the surface of the iris. It is usually associated with disease processes in the retina, which involve the retina becoming starved of oxygen (ischemic). If diagnosed early, the neovascularization can be reversed with prompt pan retinal photocoagulation (PRP), or injection of anti-VEGF medications with subsequent PRP. This condition is often associated with diabetes in advanced proliferative diabetic retinopathy. Other conditions causing rubeosis iridis include central retinal vein occlusion, ocular ischemic syndrome, ocular surgery complication and chronic retinal detachment. Intraocular injection of Bevacizumab may provide an additional strategy to the treatment of rubeosis iridis.